Vanguard Group’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $8.07B | Buy |
23,019,518
+20,873
| +0.1% | +$7.05M | 0.12% | 143 |
|
|
2025
Q3 | $7.43B | Buy |
22,998,645
+141,747
| +0.6% | +$44.1M | 0.11% | 157 |
|
|
2025
Q2 | $8.89B | Buy |
22,856,898
+704,790
| +3% | +$283M | 0.14% | 120 |
|
|
2025
Q1 | $9.64B | Buy |
22,152,108
+666,534
| +3% | +$268M | 0.17% | 100 |
|
|
2024
Q4 | $7.93B | Buy |
21,485,574
+138,380
| +0.6% | +$57.9M | 0.14% | 116 |
|
|
2024
Q3 | $11.1B | Buy |
21,347,194
+140,269
| +0.7% | +$74.9M | 0.2% | 84 |
|
|
2024
Q2 | $11.5B | Sell |
21,206,925
-24,784
| -0.1% | -$13.1M | 0.22% | 75 |
|
|
2024
Q1 | $11B | Buy |
21,231,709
+4,519
| +0% | +$2.25M | 0.22% | 74 |
|
|
2023
Q4 | $10B | Buy |
21,227,190
+23,807
| +0.1% | +$11M | 0.22% | 79 |
|
|
2023
Q3 | $9.23B | Sell |
21,203,383
-131,330
| -0.6% | -$59.6M | 0.23% | 72 |
|
|
2023
Q2 | $9.48B | Sell |
21,334,713
-137,867
| -0.6% | -$63.6M | 0.22% | 75 |
|
|
2023
Q1 | $9.87B | Sell |
21,472,580
-864
| -0% | -$411K | 0.25% | 69 |
|
|
2022
Q4 | $11B | Buy |
21,473,444
+239,661
| +1% | +$122M | 0.3% | 60 |
|
|
2022
Q3 | $9.65B | Buy |
21,233,783
+183,370
| +0.9% | +$87.7M | 0.28% | 58 |
|
|
2022
Q2 | $10.2B | Buy |
21,050,413
+277,518
| +1% | +$137M | 0.29% | 61 |
|
|
2022
Q1 | $10.2B | Buy |
20,772,895
+1,860,427
| +10% | +$850M | 0.24% | 70 |
|
|
2021
Q4 | $8.77B | Sell |
18,912,468
-15,598
| -0.1% | -$6.56M | 0.2% | 83 |
|
|
2021
Q3 | $7.06B | Buy |
18,928,066
+17,645
| +0.1% | +$6.71M | 0.18% | 95 |
|
|
2021
Q2 | $7.22B | Buy |
18,910,421
+65,981
| +0.4% | +$25.2M | 0.18% | 91 |
|
|
2021
Q1 | $6.76B | Sell |
18,844,440
-110,134
| -0.6% | -$35.4M | 0.18% | 91 |
|
|
2020
Q4 | $6.09B | Sell |
18,954,574
-375,159
| -2% | -$115M | 0.18% | 96 |
|
|
2020
Q3 | $5.19B | Sell |
19,329,733
-321,519
| -2% | -$86.5M | 0.17% | 99 |
|
|
2020
Q2 | $5.17B | Sell |
19,651,252
-354,942
| -2% | -$94.7M | 0.18% | 94 |
|
|
2020
Q1 | $4.54B | Buy |
20,006,194
+495,707
| +3% | +$135M | 0.19% | 95 |
|
|
2019
Q4 | $5.89B | Sell |
19,510,487
-4,911
| -0% | -$1.35M | 0.2% | 86 |
|
|
2019
Q3 | $4.69B | Buy |
19,515,398
+44,613
| +0.2% | +$12.2M | 0.17% | 102 |
|
|
2019
Q2 | $5.49B | Buy |
19,470,785
+146,654
| +0.8% | +$40.1M | 0.21% | 84 |
|
|
2019
Q1 | $5.55B | Buy |
19,324,131
+196,086
| +1% | +$56.7M | 0.22% | 81 |
|
|
2018
Q4 | $5.02B | Buy |
19,128,045
+398,571
| +2% | +$110M | 0.23% | 79 |
|
|
2018
Q3 | $5.13B | Buy |
18,729,474
+532,579
| +3% | +$138M | 0.2% | 87 |
|
|
2018
Q2 | $4.33B | Buy |
18,196,895
+216,648
| +1% | +$50.2M | 0.18% | 98 |
|
|
2018
Q1 | $3.95B | Buy |
17,980,247
+176,665
| +1% | +$41.5M | 0.17% | 106 |
|
|
2017
Q4 | $4.01B | Sell |
17,803,582
-174,025
| -1% | -$37.1M | 0.18% | 104 |
|
|
2017
Q3 | $3.41B | Buy |
17,977,607
+172,881
| +1% | +$32.9M | 0.16% | 120 |
|
|
2017
Q2 | $3.35B | Buy |
17,804,726
+479,046
| +3% | +$86.1M | 0.17% | 117 |
|
|
2017
Q1 | $2.87B | Buy |
17,325,680
+700,705
| +4% | +$111M | 0.15% | 129 |
|
|
2016
Q4 | $2.39B | Buy |
16,624,975
+232,327
| +1% | +$31.1M | 0.13% | 144 |
|
|
2016
Q3 | $2.05B | Buy |
16,392,648
+401,294
| +3% | +$51.8M | 0.12% | 162 |
|
|
2016
Q2 | $2.1B | Buy |
15,991,354
+386,213
| +2% | +$52.8M | 0.13% | 150 |
|
|
2016
Q1 | $2.17B | Buy |
15,605,141
+491,837
| +3% | +$65.7M | 0.14% | 135 |
|
|
2015
Q4 | $2.11B | Buy |
15,113,304
+270,474
| +2% | +$37.3M | 0.14% | 138 |
|
|
2015
Q3 | $2.08B | Buy |
14,842,830
+38,454
| +0.3% | +$5.78M | 0.15% | 125 |
|
|
2015
Q2 | $2.43B | Buy |
14,804,376
+58,018
| +0.4% | +$9.27M | 0.16% | 113 |
|
|
2015
Q1 | $2.28B | Buy |
14,746,358
+346,790
| +2% | +$49.4M | 0.15% | 121 |
|
|
2014
Q4 | $1.81B | Buy |
14,399,568
+215,000
| +2% | +$26.6M | 0.13% | 152 |
|
|
2014
Q3 | $1.7B | Buy |
14,184,568
+93,620
| +0.7% | +$10.7M | 0.13% | 148 |
|
|
2014
Q2 | $1.52B | Buy |
14,090,948
+118,103
| +0.8% | +$12.2M | 0.12% | 166 |
|
|
2014
Q1 | $1.39B | Sell |
13,972,845
-238,289
| -2% | -$21.6M | 0.12% | 167 |
|
|
2013
Q4 | $1.31B | Buy |
14,211,134
+109,355
| +0.8% | +$9.72M | 0.12% | 164 |
|
|
2013
Q3 | $1.18B | Buy |
14,101,779
+462,841
| +3% | +$39.7M | 0.12% | 167 |
|
|
2013
Q2 | $1.12B | Buy |
+13,638,938
| New | +$1.02B | 0.12% | 156 |
|
Other funds holding ELV
Vanguard Group's ELV Position: Q4 2025 in Review
Vanguard Group increased its Elevance Health (ELV) stake by 0.09% in Q4 2025, buying an estimated $7.05M and bringing the position to 23,019,518 shares worth $8.07B. The position accounts for 0.12% of the portfolio, ranked #143.
Vanguard Group first reported a position in ELV in Q2 2013 and has held it in 51 quarters since. The position peaked at $11.5B in Q2 2024. 1,555 funds tracked by Wall St. Rank hold ELV as of Q4 2025.
- Vanguard Group held 23,019,518 shares of Elevance Health worth $8.07B as of Q4 2025.
- Vanguard Group bought 20,873 Elevance Health shares in Q4 2025, an estimated $7.05M.
- Elevance Health made up 0.12% of Vanguard Group's portfolio in Q4 2025, its #143 holding.
- Vanguard Group first reported a position in Elevance Health in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Elevance Health position peaked at $11.5B in Q2 2024.
- 1,555 funds tracked by Wall St. Rank held Elevance Health as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.